Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK
But Experts Doubt It Can Overtake J&J’s Entrenched Darzalex
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.
You may also be interested in...
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.